Jun 25, 2026
Two recent studies advance Alzheimer's research: one finds combining anti-amyloid antibodies with natural compounds improves efficacy and safety, while another maps a molecular cascade that could reveal new therapeutic targets. The combination therapy study used aducanumab, lecanemab, resveratrol, and curcumin. The molecular study identified gene expression networks and proposed a two-stage disease model.
May 26, 2026
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
Apr 16, 2026
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
Mar 06, 2026
The global nuclear medicine equipment market is projected to reach USD 10.00 billion by 2035, driven by rising cancer prevalence, technological advances in hybrid imaging systems, and AI integration in diagnostic workflows.
Feb 16, 2026
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
Feb 19, 2026
Researchers at Washington University in St. Louis have adapted CAR-T immunotherapy to target aggregated amyloid-beta in mice, with transient CAR expression clearing brain plaques. The approach uses CD4+ T cells engineered with receptors based on lecanemab antibody sequences.
Feb 13, 2026
Artificial intelligence is increasingly used to analyze Alzheimer's datasets and inform drug discovery, while researchers identify promising new drug targets including the IDOL enzyme and somatostatin receptors that could lead to more affordable treatments.
